The Head and Neck Squamous Cell Carcinoma Treatment Market was valued at USD 5.2 billion in 2024 and is projected to reach USD 10.1 billion by 2034, registering a CAGR of 6.8%. This growth trajectory is underpinned by several key factors, including the rising incidence of head and neck cancers, advancements in treatment modalities, and increasing healthcare expenditure. The market is...